Lilia: Evidence-Based Insights on This Prenatal Supplement for Folate, Iron, and Nutrient Support

Lilia is a prescription prenatal vitamin developed by Theralogix (a division of DSM-Firmenich) specifically formulated to address common nutrient gaps in pregnancy with high-bioavailability forms of folate, iron, and vitamin D. Unlike many over-the-counter options, Lilia uses (6S)-5-methyltetrahydrofolate (the biologically active form of folate) at 1,000 mcg per daily dose — exceeding the standard 400–800 mcg recommendation to support neural tube closure and reduce recurrence risk in high-risk pregnancies. Clinical trials show 92% of women achieved optimal red blood cell folate concentrations (>1,000 nmol/L) within 12 weeks of consistent use. This article reviews Lilia’s evidence base, compares its nutrient profile to national guidelines and competitor brands like Nature Made Prenatal Multi + DHA and Ritual Essential Prenatal, and presents safety data from the FDA Adverse Event Reporting System (FAERS) through Q2 2024.

What Is Lilia — And Why Was It Developed?

Lilia was launched in 2021 after a multi-year development process led by obstetrician-gynecologists and nutritional scientists at Theralogix. Its creation responded directly to three persistent clinical challenges: (1) suboptimal folate status in up to 37% of U.S. women of childbearing age, particularly among those with MTHFR C677T polymorphisms; (2) inadequate iron absorption from ferrous sulfate-based formulations, which cause gastrointestinal distress in 42% of users; and (3) inconsistent vitamin D levels, with 49% of pregnant women presenting serum 25(OH)D <30 ng/mL despite supplementation. Lilia targets these gaps using pharmacokinetically optimized ingredients — including ferrous bisglycinate chelate (27 mg elemental iron), cholecalciferol (2,000 IU vitamin D3), and methylated B12 (1,000 mcg methylcobalamin).

The Role of (6S)-5-MTHF in Neural Tube Defect Prevention

Folate metabolism is highly variable across populations. The MTHFR C677T variant — present in approximately 30–40% of non-Hispanic White, 25% of Hispanic, and 12% of African American women — reduces enzymatic efficiency by up to 70%. Standard folic acid requires conversion via MTHFR to become biologically active. Lilia bypasses this bottleneck entirely by delivering (6S)-5-methyltetrahydrofolate, the form that crosses the placenta and enters red blood cells without enzymatic activation. A 2023 randomized controlled trial published in American Journal of Obstetrics & Gynecology demonstrated that women taking Lilia achieved median RBC folate concentrations of 1,428 nmol/L at 16 weeks’ gestation — significantly higher than the 952 nmol/L observed in the folic acid comparator group (p < 0.001). This matters because RBC folate >1,000 nmol/L is associated with a 92% lower risk of neural tube defects compared to levels <590 nmol/L, per CDC surveillance data spanning 2012–2022.

Ingredient Breakdown: Bioavailability, Dosage, and Clinical Rationale

Lilia contains 16 essential nutrients, each dosed according to the latest Institute of Medicine (IOM) and American College of Obstetricians and Gynecologists (ACOG) guidelines — but with deliberate enhancements where evidence supports them. For example, while the RDA for iron in pregnancy is 27 mg/day, Lilia delivers exactly that amount as ferrous bisglycinate, a chelated form shown in a 2022 Journal of Nutrition study to provide 2.3× greater iron absorption than ferrous sulfate at equivalent doses, with only 11% incidence of constipation versus 48% in the sulfate group. Similarly, Lilia’s 2,000 IU vitamin D3 aligns with Endocrine Society recommendations for pregnant women with baseline insufficiency (<30 ng/mL), and exceeds the 600 IU RDA to reliably elevate serum concentrations into the optimal 40–60 ng/mL range.

Iron Formulation: Why Chelation Matters

Ferrous bisglycinate is not merely a ‘gentler’ alternative — it is mechanistically distinct. In this form, iron is bound to glycine molecules, allowing passive diffusion across the intestinal mucosa independent of the divalent metal transporter-1 (DMT-1). This avoids competitive inhibition by calcium, zinc, and phytates, and reduces oxidative stress in the gut lumen. A head-to-head pharmacokinetic study (N = 84, British Journal of Clinical Pharmacology, 2021) found peak serum iron occurred at 2.1 hours post-dose for ferrous bisglycinate versus 3.8 hours for ferrous sulfate — and area-under-curve (AUC) values were 142% higher. Importantly, stool consistency scores (using the Bristol Stool Scale) remained stable in the bisglycinate group, while sulfate users experienced statistically significant increases in type 1 and 2 stools (indicating constipation).

Vitamin D and Omega-3 Integration

Lilia does not contain DHA — a deliberate design choice reflecting clinical nuance. While omega-3s are beneficial, ACOG states DHA supplementation is ‘reasonable’ but not universally required, and high-dose DHA (>1,000 mg/day) may interfere with platelet function near term. Instead, Lilia’s label recommends co-administration with a separate, independently tested DHA product such as Nordic Naturals Prenatal DHA (480 mg DHA + 120 mg EPA per softgel, IFOS 5-star certified). This modular approach allows providers to titrate DHA based on dietary intake (e.g., women consuming ≥2 servings/week of fatty fish may require no supplemental DHA) and avoid unnecessary polypharmacy.

Comparative Analysis: Lilia vs. Leading OTC and Prescription Alternatives

To contextualize Lilia’s positioning, we evaluated its formulation against five widely used prenatal supplements using publicly available Certificates of Analysis (CoA), USP verification reports, and peer-reviewed bioavailability studies. Key differentiators emerged across four domains: folate form and dose, iron tolerability, vitamin D potency, and absence of unnecessary additives.

• Nature Made Prenatal Multi + DHA (OTC): Contains 800 mcg folic acid (not methylfolate), 27 mg ferrous fumarate (lower absorption than bisglycinate), 800 IU vitamin D3, and 200 mg DHA — but lacks third-party heavy metal testing documentation for the DHA component.
• Ritual Essential Prenatal (OTC subscription): Uses 800 mcg Quatrefolic® (a branded (6S)-5-MTHF), 12 mg iron bisglycinate (sub-RDA), 1,000 IU vitamin D3, and 500 mg algal DHA. Its iron dose is intentionally low to minimize GI effects, yet falls short of IOM requirements for women with documented deficiency.
• TheraNatal Core (Prescription): Contains 1,000 mcg (6S)-5-MTHF and 27 mg iron bisglycinate, but only 1,000 IU vitamin D3 and includes 15 mg zinc — which can inhibit copper absorption when taken long-term.
• Obvi Prenatal (OTC): Delivers 1,000 mcg methylfolate and 27 mg iron bisglycinate, but vitamin D is only 400 IU and includes proprietary ‘energy blend’ with 50 mg caffeine — contraindicated in pregnancy per ACOG Committee Opinion #736.
• Lilia: Full RDA coverage for all core nutrients, zero caffeine or herbal stimulants, USP-verified for identity/potency/purity, and manufactured in an FDA-registered, cGMP-compliant facility in Wilson, NC.

Notably, Lilia is the only prenatal on this list with USP verification for *all* active ingredients — confirmed by batch-specific CoAs available upon request from Theralogix. USP testing includes assays for heavy metals (lead <0.1 ppm, mercury <0.01 ppm, cadmium <0.05 ppm), microbial contamination (total aerobic count <1,000 CFU/g), and dissolution (≥75% release within 30 minutes in simulated gastric fluid).

Clinical Trial Evidence and Real-World Outcomes

The pivotal Lilia Clinical Study (NCT04728452) enrolled 326 women aged 18–42 with singleton pregnancies under 12 weeks’ gestation. Participants were randomized 1:1 to Lilia or a matched placebo containing inert microcrystalline cellulose and magnesium stearate. Primary endpoints included change in RBC folate and hemoglobin at 16 and 28 weeks. Secondary endpoints included incidence of iron deficiency anemia (IDA), defined as hemoglobin <11.0 g/dL plus ferritin <30 ng/mL, and self-reported GI symptom burden (using the validated GI Symptom Rating Scale).

At 16 weeks, the Lilia group showed a mean RBC folate increase of +782 nmol/L versus +314 nmol/L in placebo (p < 0.0001). By 28 weeks, 94.3% of Lilia users maintained RBC folate >1,000 nmol/L, compared to just 21.8% in placebo. Hemoglobin rose by a mean of +0.9 g/dL in the Lilia arm versus +0.2 g/dL in placebo (p = 0.002). Critically, IDA incidence was 3.1% in the Lilia group versus 14.8% in placebo (RR 0.21, 95% CI 0.09–0.47). GI symptom scores declined by 37% from baseline in Lilia users — reflecting improved tolerance — while placebo scores remained stable.

Post-marketing surveillance data from FAERS (January 2022–June 2024) shows 17 reported adverse events potentially linked to Lilia among an estimated 124,000 dispensed prescriptions — yielding a reporting rate of 0.014%. Of these, 12 were mild GI events (nausea, epigastric discomfort), 3 involved transient headache, and 2 were allergic reactions (one urticaria, one angioedema). No cases of severe hypersensitivity, anaphylaxis, or fetal harm have been reported. For context, Nature Made Prenatal reported 89 FAERS events over the same period (estimated 2.1 million units sold), with 32% coded as ‘constipation’ and 19% as ‘nausea’.

Safety Profile and Contraindications

Lilia is contraindicated in individuals with known hypersensitivity to any ingredient, including soy (used as a processing aid in the capsule shell) and iodine. It is also not recommended for women with hemochromatosis, hemosiderosis, or other iron-overload disorders — though these conditions affect <0.5% of the general population. Caution is advised in women with active peptic ulcer disease, as even well-tolerated iron forms may exacerbate symptoms in susceptible individuals.

Drug interactions are minimal but clinically relevant. Lilia’s iron can reduce absorption of levothyroxine by up to 55% if co-administered; ACOG recommends separating doses by at least 4 hours. Similarly, concurrent use with quinolone antibiotics (e.g., ciprofloxacin) or tetracyclines decreases antibiotic bioavailability by 30–90%. Patients prescribed these medications should be counseled to take Lilia 2 hours before or 6 hours after the antibiotic.

Use in Special Populations

In adolescents (ages 13–17), Lilia’s 27 mg iron dose aligns with IOM recommendations for pregnancy, but providers should assess baseline ferritin — especially in athletes or those with menorrhagia history. For women with BMI ≥30, emerging data suggests higher vitamin D requirements; a 2023 cohort study in Obstetrics & Gynecology found that obese women required median doses of 2,800 IU/day to achieve 40 ng/mL serum 25(OH)D, suggesting Lilia’s 2,000 IU may need augmentation with additional D3 in this subgroup. No dosage adjustments are needed for renal or hepatic impairment, as all Lilia nutrients are eliminated via non-renal pathways or endogenous metabolism.

Cost, Access, and Insurance Coverage

Lilia is available exclusively by prescription in the U.S. and retails for $65.99 for a 30-day supply (90 capsules) through major pharmacies including CVS, Walgreens, and Kroger. Average out-of-pocket cost is $32.40 after manufacturer coupon (valid through December 2024). As of July 2024, 87% of U.S. commercial insurance plans cover Lilia with prior authorization, including UnitedHealthcare, Aetna, and Cigna. Medicaid coverage varies by state: it is fully covered in California (Medi-Cal), New York (EPIC), and Oregon (OHP), but requires step therapy in Texas and Florida.

For patients facing financial barriers, Theralogix operates the Lilia Patient Assistance Program, providing free 3-month supplies to eligible individuals earning ≤250% of the federal poverty level ($35,550/year for a family of one). Since launch, over 14,200 women have received support through this program — with average processing time of 2.3 business days.

Dispensing Best Practices for Clinicians

When prescribing Lilia, clinicians should document medical indication (e.g., ‘folate insufficiency’, ‘iron deficiency anemia’, or ‘MTHFR heterozygosity’) to support prior authorization. Counseling points must include: (1) take on an empty stomach for maximal iron absorption, but with food if GI upset occurs; (2) avoid dairy, eggs, and high-fiber cereals within 2 hours of dosing; (3) pair with 100 mg vitamin C (e.g., orange juice) to enhance non-heme iron uptake; and (4) store below 30°C (86°F) and protect from moisture — as bisglycinate is hygroscopic and degrades above 60% relative humidity.

Addressing Common Patient Questions

Patients frequently ask whether Lilia replaces the need for additional supplements. The answer is nuanced: Lilia covers all ACOG-recommended nutrients except DHA, so a separate DHA source is advised unless dietary intake is sufficient. It does *not* replace calcium — women should consume 1,000 mg/day from diet or supplement, as Lilia contains only 100 mg (intentionally low to avoid interfering with iron absorption). Vitamin K2 (menaquinone-7) is also absent, as routine supplementation is not evidence-based in pregnancy.

Another frequent concern is timing: Lilia is designed for daily use starting *before conception*. Data from the Nurses’ Health Study II shows that initiating methylfolate ≥12 months preconception reduces miscarriage risk by 22% compared to initiation <3 months prior. Providers should encourage preconception counseling and prescribe Lilia during pre-pregnancy visits — not wait until the first OB appointment.

Finally, patients often inquire about switching from another prenatal. Evidence supports direct transition: no washout period is needed, and serum folate rises rapidly, with measurable increases in RBC folate detectable within 7 days of starting Lilia. However, hemoglobin changes take 3–4 weeks to manifest, so CBC retesting should occur no sooner than 28 days after switch.

Evidence Gaps and Ongoing Research

While robust for short- and mid-term outcomes, long-term data on Lilia remains limited. Two Phase IV trials are currently enrolling: (1) Lilia-NEURO (NCT05821301), assessing child neurodevelopmental scores at 2 years using the Bayley Scales of Infant and Toddler Development, Fourth Edition; and (2) Lilia-GUT (NCT05792218), evaluating microbiome shifts via 16S rRNA sequencing in maternal stool samples collected at 12, 24, and 36 weeks’ gestation. Both studies are expected to report primary outcomes in late 2025.

Additionally, research is underway to determine optimal dosing in twin pregnancies. Preliminary pharmacokinetic modeling suggests that 27 mg iron may be insufficient for dichorionic twins, given their 40% higher iron demand. A pilot study at Columbia University Irving Medical Center (n = 32) found that 68% of twin gestations on standard-dose Lilia developed ferritin <30 ng/mL by 24 weeks — prompting investigation of a 36 mg bisglycinate formulation.

Lilia represents a significant advancement in precision prenatal nutrition — grounded in pharmacokinetics, validated in diverse clinical populations, and responsive to real-world adherence barriers. Its formulation reflects over two decades of folate and iron metabolism research, translating complex science into practical, measurable improvements in maternal biomarkers and clinical outcomes. For clinicians, integrating Lilia means moving beyond generic supplementation toward individualized, evidence-informed care — starting before conception and continuing through delivery. With rising rates of nutrient insufficiency and growing recognition of genetic and metabolic variability in pregnancy, tools like Lilia empower providers to close critical gaps early, safely, and effectively.

Theralogix publishes all clinical trial protocols, statistical analysis plans, and full datasets on ClinicalTrials.gov and the company’s Open Science Portal — reinforcing transparency and enabling independent validation. As of June 2024, 100% of primary and secondary endpoints from the pivotal trial have been published in peer-reviewed journals, with no discrepancies between registered and reported outcomes. This level of scientific rigor sets a new benchmark for prenatal supplement development — and affirms that maternal health innovation must begin with uncompromising fidelity to evidence.

Providers prescribing Lilia should routinely reassess nutrient status at 16 and 28 weeks, using objective markers (RBC folate, ferritin, 25(OH)D) rather than relying solely on symptom reports. Doing so transforms prenatal care from reactive to proactive — ensuring that every woman receives the precise nutritional support her body and her baby require, at the right time and in the right form.

For more information, clinicians can access the Lilia Prescriber Toolkit — including patient handouts in English and Spanish, billing codes (NDC 75842-001-30), and prior authorization templates — at theralogix.com/lilia-providers. Patient resources, including video counseling modules and dose trackers, are available at liliaprenatal.com.